Financial Performance - Total revenue for the year ended June 30, 2025, was RMB 711.5 million, a decrease of 34.7% compared to RMB 1,089.0 million in 2024[3] - Gross profit for the same period was RMB 113.4 million, down 37.0% from RMB 179.9 million in the previous year[3] - The company reported an operating loss of RMB 25.5 million, a decline of RMB 25.6 million from a profit of RMB 0.1 million in 2024[3] - Net loss for the year was RMB 25.7 million, compared to a profit of RMB 0.6 million in 2024, representing a decrease of RMB 26.3 million[3] - Basic loss per share was RMB 32.46, down from earnings of RMB 0.62 per share in the previous year, a decline of RMB 33.08[5] - The gross profit margin decreased to 15.9%, down 0.6 percentage points from 16.5% in 2024[3] - For the fiscal year ending June 30, 2025, total revenue was RMB 774,379,000, a decrease from RMB 1,214,697,000 in the previous year, representing a decline of approximately 36.3%[24] - The company reported a net loss of RMB 25,674,000 for the fiscal year ending June 30, 2025, compared to a net profit of RMB 580,000 in the previous year[24][25] - The loss attributable to the owners of the company was RMB 26.0 million, compared to a profit of RMB 0.4 million in the previous year[50] Assets and Liabilities - Total assets decreased to RMB 447.6 million from RMB 692.9 million in 2024, a decline of 35.4%[6] - Current assets fell to RMB 171.0 million, down from RMB 295.7 million in the previous year, a decrease of 42.1%[6] - Total liabilities decreased to RMB 130.0 million from RMB 340.0 million in 2024, a reduction of 61.8%[7] - The total assets as of June 30, 2025, amounted to RMB 447,603,000, a decrease from RMB 692,877,000 in the previous year, indicating a reduction of approximately 35.3%[24][25] - The total liabilities as of June 30, 2025, were RMB 130,029,000, down from RMB 339,992,000, reflecting a decrease of about 61.8%[24][25] Cash Flow and Financing - The company recorded a net cash outflow from operating activities of RMB 59.8 million for the year[9] - The net cash flow used in operating activities was RMB 59.8 million, a decrease from RMB 101.7 million in the previous year, primarily due to reduced revenue leading to lower inventory purchases[61] - The company has sufficient resources to continue operations for at least the next 12 months, with no significant uncertainties affecting its ability to continue as a going concern[10] - As of June 30, 2025, the company has available but undrawn bank financing of RMB 50,000,000 and loans from former joint ventures amounting to RMB 40,000,000[11] - The company continues to negotiate external financing options, including obtaining further loan financing and refinancing existing loans[11] Operational Changes - The company has closed several loss-making retail stores to minimize cash outflows, which is expected to improve operating profit margins and cash flow[11] - The company has implemented cost control measures to enhance operational efficiency and improve future cash flows[11] - The company has reduced its brand product offerings by 315, maintaining a total of 223 brand products by the end of the year[44] - The company operates a total of 120 chain stores, with a projected increase to 203 stores by 2024[41] - The active customer base in the national distribution network fell to approximately 1,027 from 1,515 in the previous year, with a notable decline in both retail and distributor customers[54] Revenue Breakdown - Revenue from external customers for the year ended June 30, 2025, was RMB 711,509,000, a decrease from RMB 1,089,037,000 for the year ended June 30, 2024[21] - The breakdown of revenue for the year ended June 30, 2025, includes RMB 140,374,000 from prescription drugs and RMB 502,432,000 from over-the-counter drugs[21] - The revenue from external customers for the distribution segment was RMB 513,626,000, while the retail segment generated RMB 197,883,000, contributing to a total external revenue of RMB 711,509,000[24] - The retail business revenue for the year was RMB 197.9 million, a year-on-year decrease of 40.4%[41] - The distribution business revenue was RMB 513.6 million, down 32.1% year-on-year[42] Employee and Operational Metrics - Employee benefit expenses decreased to RMB 68,195,000 in 2025 from RMB 113,440,000 in 2024, a reduction of about 40%[27] - As of June 30, 2025, the group had 842 full-time employees, a decrease from 1,286 in 2024, with total employee benefits expenditure amounting to RMB 68.2 million, down from RMB 113.4 million in 2024[67] Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adopted the corporate governance code as per listing rules, ensuring compliance with applicable provisions[75] - The audit committee consists of three independent non-executive directors, responsible for overseeing the group's financial data and reporting processes[76] - The group's auditor confirmed that the figures in the annual performance announcement align with the audited consolidated financial statements[77] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set forth in the listing rules[78] Strategic Initiatives - The company plans to focus on the health sector, particularly the pharmaceutical industry, while optimizing its retail network and exploring structural transformation and digital upgrades[69] - The "Professional+" strategy aims to enhance service professionalism and operational quality, leveraging pharmacists and business school advantages to improve pharmaceutical service levels[69] - The "Platform+" strategy will expand value-added services in stores to meet growing consumer health demands, including aging and chronic disease management[70] - The "Internet+" strategy will strengthen the connection between physical stores and online platforms, utilizing new technologies and marketing ecosystems to enhance competitiveness[70] Market Trends - The Chinese government is increasingly focusing on the development of traditional Chinese medicine, with policies aimed at promoting high-quality development in the healthcare sector[36] - The market size of China's health industry is projected to reach RMB 29.1 trillion by 2030, driven by aging population and rising health awareness[36] - Technological innovations such as AI, big data, and IoT are being widely applied in healthcare, enhancing diagnostic efficiency and service quality[37] - The company is expected to accelerate the construction of elderly care service systems and improve service quality in 2024[37] - The company is focusing on community and home-based elderly care services to meet diverse aging needs[37]
大健康国际(02211) - 2025 - 年度业绩